Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03224819 · ClinicalTrials.gov registry record · Early Phase 1
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Early Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 46
- Enrollment target
NCT03224819 is a Early Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 46 participants.
The verdict
NCT03224819, a Early Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the safety and tolerability of emerfetamab in adults with relapsed/refractory acute myeloid leukemia (AML) and to estimate the maximum tolerated dose (MTD) and/or a biologically active dose (eg, recommended phase 2 dose \[RP2D\]).
Interventions
- DRUG Emerfetamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2017-09-07 |
| Est. Completion | 2020-12-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03224819
The ClinicalTrials.gov registry entry for NCT03224819 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Emerfetamab is the first listed.
NCT03224819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03224819 about?
NCT03224819 is a clinical study titled "Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)". The primary objectives of this study are to evaluate the safety and tolerability of emerfetamab in adults with relapsed/refractory acute myeloid leukemia (AML) and to estimate the maximum tolerated dose (MTD) and/or a biologically active dose (eg, recommended phase 2 dose \[RP2D\]).
What is the current status of trial NCT03224819?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 46 participants. The study started on 2017-09-07. Estimated completion is 2020-12-28.
What interventions are being tested in trial NCT03224819?
The interventions under investigation include: Emerfetamab (DRUG).
Who is sponsoring clinical trial NCT03224819?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.